{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:16:37Z","timestamp":1782602197984,"version":"3.54.5"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.9010-17","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T22:12:19Z","timestamp":1509487939000},"page":"253-258","source":"Crossref","is-referenced-by-count":25,"title":["Daptomycin-induced Eosinophilic Pneumonia and a Review of the Published Literature"],"prefix":"10.2169","volume":"57","author":[{"given":"Yoshitsugu","family":"Higashi","sequence":"first","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Ogami","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koyomi","family":"Kawago","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Tokui","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Sakamaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47: 2538-2544, 2003.","DOI":"10.1128\/AAC.47.8.2538-2544.2003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fowler VG Jr, Boucher HW, Corey R, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by <i>Staphylococcus aureus<\/i>. N Engl J Med 355: 653-665, 2006.","DOI":"10.1056\/NEJMoa053783"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38: 1673-1681, 2004.","DOI":"10.1086\/420818"},{"key":"4","unstructured":"4. Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM, Nambiar S. Eosinophilic pneumonia in patients treated with daptomycin: Review of the literature and US FDA adverse event reporting system reports. Drug Saf 35: 447-457, 2012."},{"key":"5","unstructured":"5. Package insert. Cubicin (daptomycin) Injection, Cubist Pharmaceuticals, Lexington, MA: November 2010."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hayes D Jr, Anstead MI, Kuhn RJ. Eosinophilic pneumonia induced by daptomycin. J Infect 54: 211-213, 2007.","DOI":"10.1016\/j.jinf.2006.11.006"},{"key":"7","unstructured":"7. Miller BA, Gray A, Leblanc TW, Sexton DJ, Martin AR, Slama TG. Acute eosinophilic pneumonia secondary to daptomycin: A report of three cases. Clin Infect Dis 50: e63-e68, 2010."},{"key":"8","unstructured":"8. Kalogeropoulos AS, Tsiodras S, Loverdos D, Fanourgiakis P, Skoutelis A. Eosinophilic pneumonia associated with daptomycin: A case report and a review of the literature. J Med Case Rep 5: 13, 2011."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Allen JN. Drug-induced eosinophilic lung disease. Clin Chest Med 25: 77-88, 2004.","DOI":"10.1016\/S0272-5231(03)00141-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cobb E, Kimbrough RC, Nugent KM, Phy MP. Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin. Ann Pharmacother 41: 696-701, 2007.","DOI":"10.1345\/aph.1H372"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kakish E, Wiesner AM, Winstead PS, Bensadoun ES. Acute respiratory failure due to daptomycin induced eosinophilic pneumonia. Respir Med 1: 235-237, 2008.","DOI":"10.1016\/j.rmedc.2008.07.010"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shinde A, Seifi A, DelRe S, Moustafa Hussein WH, Ohebsion J. Daptomycin-induced pulmonary infiltrates with eosinophilia. J Infect 58: 173-174, 2009.","DOI":"10.1016\/j.jinf.2008.11.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lal Y, Assimacopoulos P. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 50: 737-740, 2010.","DOI":"10.1086\/650487"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Rether C, Conen A, Grossenbacher M, Albrich WC. A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia. Infection 39: 583-585, 2011.","DOI":"10.1007\/s15010-011-0148-y"},{"key":"15","unstructured":"15. Kagawa N, Tamagaki G, Sugiyama Y, Ijiri N, Kamoi H, Hirata K. A case of acute eosinophilic pneumonia probably induced by daptomycin. Nihon Kokyuki Gakkai Zasshi 2: 284-288, 2013 (in Japanese, Abstract in English)."},{"key":"16","unstructured":"16. Phillips J, Cardile AP, Patterson TF, Lewis JS. Daptomycin-induced acute eosinophilic pneumonia: Analysis of the current data and illustrative case reports. Scand J Infect Dis 45: 804-808, 2013."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yusuf E, Perrottet N, Orasch C, Borens O, Trampuz A. Daptomycin-associated eosinophilic pneumonia in two patients with prosthetic joint infection. Surg Infect 15: 834-837, 2014.","DOI":"10.1089\/sur.2013.200"},{"key":"18","unstructured":"18. Patel JJ, Antony A, Herrera M, Lipchik RJ. Daptomycin-induced acute eosinophilic pneumonia. WMJ 113: 199-201, 2014."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hagiya H, Hasegawa K, Asano K, et al. Myopathy and eosinophilic pneumonia coincidentally induced by treatment with daptomycin. Intern Med 54: 525-529, 2015.","DOI":"10.2169\/internalmedicine.54.3397"},{"key":"20","unstructured":"20. Tujimoto K, Toki H, Ogawa Y, Yamato H, Miyake Y, Kodama K. A case of acute eosinophilic pneumonia probably induced by daptomycin. Nihon Kokyuki Gakkai Zasshi 4: 468-472, 2015 (in Japanese, Abstract in English)."},{"key":"21","unstructured":"21. Wojtaszczyk A, Jankowich M. Dyspnea on daptomycin: eosinophilic pneumonia. R I Med J 98: 41-43, 2015."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Roux S, Ferry T, Chidiac C, Valour F. Daptomycin-induced eosinophilic pneumonia. Int J Infect Dis 37: 95-96, 2015.","DOI":"10.1016\/j.ijid.2015.06.010"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Chiu SY, Faust AC, Dand HM. Daptomycin-induced eosinophilic pneumonia treated with intravenous corticosteroids. J Pharm Pract 28: 275-279, 2015.","DOI":"10.1177\/0897190014568678"},{"key":"24","unstructured":"24. Akcaer M, Karakas A, Tok D, Coskun O. Eosinophilic pneumonia: Daptomycin-induced lung complication. Med Mal Infect 46: 166-168, 2016."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hatipoglu M, Memis A, Turhan V, Mutluglu M, Canoglu K. Possible daptomycin-induced acute eosinophilic pneumonia in a patient with diabetic foot infection. Int J Antimicrob Agents 47: 414-415, 2016.","DOI":"10.1016\/j.ijantimicag.2016.02.014"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59: 809-920, 2004.","DOI":"10.1111\/j.1398-9995.2004.00547.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yoshioka D, Ishii H, Hatano Y, et al. A case of eosinophilic pneumonia in a tobacco harvester. Allergol Int 60: 551-554, 2011.","DOI":"10.2332\/allergolint.11-CR-0314"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clin Chest Med 25: 65-75, 2004.","DOI":"10.1016\/S0272-5231(03)00144-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47: 1318-1323, 2003.","DOI":"10.1128\/AAC.47.4.1318-1323.2003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 65: 1252-1257, 2010.","DOI":"10.1093\/jac\/dkq109"},{"key":"31","unstructured":"31. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 15: 1568-1574, 2010."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/2\/57_9010-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:27:23Z","timestamp":1659745643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/2\/57_9010-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9010-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}